Gilgamesh – Talk Bio

Actionable Insights Powered by AI

AbbVie Buys Gilgamesh’s Psychedelic Drug Bretisilocin for $1.2B

2 weeks ago talkbio0Tagged AbbVie, Acquisition, bretisilocin, Dosage Forms, Gilgamesh, GM-2505, Hallucinogens, mental health, Neuroscience discipline

AbbVie; Gilgamesh Pharmaceuticals; psychedelic drug; bretisilocin; GM-2505; major depressive disorder; acquisition; mental health; neuroscience; pharmaceutical deal

AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership

1 year ago talkbio0Tagged AbbVie, Drug Development, Gilgamesh, Hallucinogens, Mental disorders, mental health, Neuroscience discipline, next-generation

AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.